Homocyst(e)ine-Lowering Therapy Does Not Affect Plasma Asymmetrical Dimethylarginine Concentrations in Patients with Peripheral Artery Disease | Zendy

Sophie Ziegler | Zendy; Friedrich Mittermayer | Zendy; Christina Plank | Zendy; Erich Minar | Zendy; Michael Wolzt | Zendy; G. Schernthaner | Zendy

Open Access

Homocyst(e)ine-Lowering Therapy Does Not Affect Plasma Asymmetrical Dimethylarginine Concentrations in Patients with Peripheral Artery Disease

Author(s) -

Sophie Ziegler,

Friedrich Mittermayer,

Christina Plank,

Erich Minar,

Michael Wolzt,

G. Schernthaner

Publication year - 2005

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2004-1087

Subject(s) - medicine , endocrinology , asymmetric dimethylarginine , homocysteine , placebo , endothelial dysfunction , blood plasma , arginine , chemistry , biochemistry , amino acid , alternative medicine , pathology

Elevated plasma asymmetrical dimethylarginine (ADMA) is suggested to contribute to hyperhomocyst(e)ine-related vascular dysfunction in patients with peripheral artery disease (PAD). The present trial investigated whether homocyst(e)ine (Hcy)-lowering therapy with vitamin-B (vit-B) and folic acid affects plasma concentrations of ADMA in patients with PAD and hyperhomocyst(e)inemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research